Evidence map›Paper›PMID 29441336›Full record

ArticleAnnals of surgical treatment and research2018

A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma.

Hae Won Lee, Jeong Min Lee, Jung-Hwan Yoon, Yoon Jun Kim, Joong-Won Park, Sang-Jae Park, Seong Hoon Kim, Nam-Joon Yi, Kyung-Suk Suh

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical treatment and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 10 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 10 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Guideline
  9. Guideline
  10. Pooled it
  11. Article
  12. Article
  13. Article
  14. Article
  15. Long-term outcomes of thermal ablationWorld journal of clinical oncology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hae Won LeeDepartment of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Jeong Min LeeDepartment of Radiology, Seoul National University College of Medicine, Seoul, Korea.
Jung-Hwan YoonDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Yoon Jun KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Joong-Won ParkLiver Cancer Center, National Cancer Center, Goyang, Korea.
Sang-Jae ParkLiver Cancer Center, National Cancer Center, Goyang, Korea.
Seong Hoon KimLiver Cancer Center, National Cancer Center, Goyang, Korea.
Nam-Joon YiDepartment of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Kyung-Suk SuhDepartment of Surgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9535-7349
Seoul National University · KRNational Cancer Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough there are several prospective clinical studies comparing radiofrequency ablation (RFA) and hepatic resection (HR) for the treatment of hepatocellular carcinoma, there are few trials that have been performed in strictly homogeneous patients.

methodsPatients who were newly diagnosed with a solitary hepatocellular carcinoma were randomized to the HR or RFA group. Inclusion criteria were as follows: age ≥ 20 years but ≤ 70 years, Child-Pugh class A, maximal diameter of the tumor ≥ 2 cm but ≤ 4 cm, no previous treatment history, and platelet count > 80,000/mm

resultsAlthough the study was early terminated, 29 and 34 patients were enrolled in the HR and RFA groups, respectively, and prospectively followed on an intention-to-treat basis. The 5-year overall survival rates were 83.4% and 86.2% in the HR and RFA groups, respectively, which were not significantly different (P = 0.812 by log-rank, P = 0.990 by Breslow). The 3- and 5-year disease-free survival rates in the HR group were significantly superior to those in the RFA group (66.7%, 44.4%

conclusionHR was significantly superior to RFA in terms of disease-free survival; however, the overall survival was excellent in both groups.

Indexed as

Catheter ablationDisease-free survivalHepatectomyHepatocellular carcinomaRandomized controlled trial

Identifiers

PMID29441336
PMCPMC5801331
OpenAlexW2785388150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.